What are the combination treatment options for durvalumab (durvalumab)? What is the effect of combining it with osimertinib?

Durvalumab is an immune checkpoint inhibitor and an anti-PD-L1 antibody. It is mainly used to treat various malignant tumors such as non-small cell lung cancer (NSCLC) and bladder cancer. By blocking the binding of PD-L1 to PD-1, durvalumab can activate the patient's immune system and enhance the recognition and attack of tumor cells by T cells. In recent years, the application of durvalumab in tumor immunotherapy has been continuously expanded, especially in combination therapy, and has achieved remarkable results.
Common combination treatment options
Durvalumab combined with chemotherapy: Durvalumab is often used in combination with chemotherapy drugs, especially in the treatment of non-small cell lung cancer. In the IMpower150 trial, durvalumab was combined with chemotherapy (such as pemetrexed and carboplatin) to significantly improve the treatment effect and extend progression-free survival (PFS) and overall survival (OS). This option is especially suitable for patients who are unable to undergo targeted therapy or for whom immunotherapy alone is ineffective. Through combined chemotherapy, chemotherapy drugs can directly kill tumor cells, while durvalumab activates the immune system and jointly inhibits tumor growth.
Durvalumab combined with targeted therapy: In addition to chemotherapy, durvalumab can also be used in combination with targeted therapy drugs, especially for patients with EGFR-mutant non-small cell lung cancer. For patients with EGFR mutations, targeted therapy such as Osimertinib has become the standard treatment, and combination with immune checkpoint inhibitors such as durvalumab may further improve the therapeutic effect.

Durvalumab combined with other immunotherapies: In some clinical studies, durvalumab has also been combined with other immune checkpoint inhibitors such as anti-CTLA-4 antibodies to enhance the immune response. By blocking multiple immune escape pathways at the same time, the patient's immune system can be more effectively mobilized and the anti-tumor immune response can be improved. For example, combined with Ipilimumab, it can have a stronger activation effect on the immune system in some patients.

The combined effect of durvalumab and osimertinib
Osimertinib is a targeted drug targeting EGFR mutations and has become a first-line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Osimertinib prevents the proliferation and spread of cancer cells by inhibiting the activation of EGFR mutant receptors. Osimertinib has demonstrated strong efficacy in the treatment of patients with EGFR mutations and has fewer side effects than traditional chemotherapy.
Potential of combination therapy
The strategy of combining durvalumab with osimertinib is emerging as a new research direction. In patients with EGFR-mutated non-small cell lung cancer, the efficacy of immunotherapy as a single agent may not be as significant as EGFR-targeted therapy. Traditional immunotherapy may fail to effectively activate the patient's immune system because of the tumor immune evasion mechanism caused by EGFR mutations. Therefore, the combination of durvalumab and osimertinib can work at two levels: on the one hand, osimertinib targets EGFR mutations and directly inhibits the proliferation of tumor cells; on the other hand, durvalumab removes the "brakes" of the immune system, allowing T cells to recognize and attack tumors more effectively.
Clinical studies have shown that combined treatment with durvalumab and osimertinib can prolong the survival of patients with EGFR mutation-positive non-small cell lung cancer. Although monotherapy with EGFR-targeted drugs is effective, resistance may occur in some patients, and immunotherapy can restore anti-tumor activity by activating the immune system. Especially for patients with EGFR mutated lung cancer who have developed drug resistance, combination therapy is expected to provide a new treatment option.
Clinical Research and Practical Application
On the clinical research front, multiple trials are evaluating durvalumab in combination with osimertinib. For example, the ENIGMA trial explored the effects of this combination. Preliminary results show that the combination treatment of durvalumab and osimertinib has certain advantages in improving progression-free survival compared with single-agent treatment, and some patients did not develop drug resistance after combined treatment, extending the effectiveness of the treatment.
However, some studies have pointed out that the use of immune checkpoint inhibitors may increase some immune-related side effects, such as pneumonia, liver damage, etc. Therefore, in practical applications, the patient's condition and immune system status need to be carefully evaluated to ensure the safety of the treatment.
Combination regimens of durvalumab, especially in combination with chemotherapy, targeted therapies (such as osimertinib) and other immunotherapy drugs, have made significant progress in the treatment of various cancers including non-small cell lung cancer. The combined use of durvalumab and osimertinib can give full play to the complementary effects of targeted therapy and immunotherapy, and has great therapeutic potential especially in patients with EGFR mutation-positive patients. With the deepening of clinical research, this combination therapy may become an important option for the treatment of advanced or drug-resistant non-small cell lung cancer in the future.
Reference: https://www.imfinzi.com/